Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

NCT04936295 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Fulvestrant plus Anlotinib

Sponsor

Sun Yat-sen University